MPM remains difficult to treat and has an overall poor prognosis despite current
multimodality treatment. Thoracoscopy with multiple pleural biopsies can provide adequate …

Malignant pleural mesothelioma (MPM) represents a significant diagnostic and therapeutic
challenge and is almost always a fatal disease. Imaging abnormalities are common, but …

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options.
Recent advances have led to US Food and Drug Administration approvals and changes in …

Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by very poor
prognosis and lack of treatment options. Immunotherapy has rapidly emerged as an effective …

Malignant pleural mesothelioma (MPM) is a tumour which, despite progress in diagnostic
procedures and biomolecular research, has poor prognosis. Symptoms reflect extension of …

Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy of the pleura,
with a strong causal link to asbestos exposure. MPM incidence has been increasing in …

The European Respiratory Society (ERS)/European Society of Thoracic Surgeons
(ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for …

Mesothelioma is an insidious mesothelial neoplasm originating in the pleura, pericardium,
peritoneum, or tunica vaginalis, with approximately 80% of cases involving the thorax. The …

Abstract Purpose of Review Malignant pleural mesothelioma (MPM) is an incurable disease,
and its global incidence is predicted to rise. The epidemiology is changing especially in …

Malignant pleural mesothelioma (MPM) is a deadly disease that produces a significant
worldwide health care burden. The majority of cases are associated with prior asbestos …